BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22564771)

  • 1. Ischemia/reperfusion-induced myosin light chain 1 phosphorylation increases its degradation by matrix metalloproteinase 2.
    Cadete VJ; Sawicka J; Jaswal JS; Lopaschuk GD; Schulz R; Szczesna-Cordary D; Sawicki G
    FEBS J; 2012 Jul; 279(13):2444-54. PubMed ID: 22564771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined subthreshold dose inhibition of myosin light chain phosphorylation and MMP-2 activity provides cardioprotection from ischaemic/reperfusion injury in isolated rat heart.
    Cadete VJ; Sawicka J; Bekar LK; Sawicki G
    Br J Pharmacol; 2013 Sep; 170(2):380-90. PubMed ID: 23822644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ischemia induced peroxynitrite dependent modifications of cardiomyocyte MLC1 increases its degradation by MMP-2 leading to contractile dysfunction.
    Polewicz D; Cadete VJ; Doroszko A; Hunter BE; Sawicka J; Szczesna-Cordary D; Light PE; Sawicki G
    J Cell Mol Med; 2011 May; 15(5):1136-47. PubMed ID: 20518849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Degradation of cardiac myosin light chain kinase by matrix metalloproteinase-2 contributes to myocardial contractile dysfunction during ischemia/reperfusion.
    Gao L; Zheng YJ; Gu SS; Tan JL; Paul C; Wang YG; Yang HT
    J Mol Cell Cardiol; 2014 Dec; 77():102-12. PubMed ID: 25451385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2.
    Sawicki G; Leon H; Sawicka J; Sariahmetoglu M; Schulze CJ; Scott PG; Szczesna-Cordary D; Schulz R
    Circulation; 2005 Jul; 112(4):544-52. PubMed ID: 16027249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac dysfunction in an animal model of neonatal asphyxia is associated with increased degradation of MLC1 by MMP-2.
    Doroszko A; Polewicz D; Sawicka J; Richardson JS; Cheung PY; Sawicki G
    Basic Res Cardiol; 2009 Nov; 104(6):669-79. PubMed ID: 19452190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of MMP-2 expression with siRNA increases baseline cardiomyocyte contractility and protects against simulated ischemic reperfusion injury.
    Lin HB; Cadete VJ; Sra B; Sawicka J; Chen Z; Bekar LK; Cayabyab F; Sawicki G
    Biomed Res Int; 2014; 2014():810371. PubMed ID: 25147815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase-2 is activated during ischemia/reperfusion in a model of myocardial infarction.
    Cadete VJ; Arcand SA; Chaharyn BM; Doroszko A; Sawicka J; Mousseau DD; Sawicki G
    Can J Cardiol; 2013 Nov; 29(11):1495-503. PubMed ID: 23770015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effect of inhibitors of MMPs and ROS-dependent modifications of contractile proteins on protection hearts subjected to oxidative stress.
    Sawicki G
    Curr Pharm Des; 2014; 20(9):1345-8. PubMed ID: 23978100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-NAME improves doxycycline and ML-7 cardioprotection from oxidative stress.
    Bil-Lula I; Krzywonos-Zawadzka A; Sawicka J; Bialy D; Wawrzynska M; Wozniak M; Sawicki G
    Front Biosci (Landmark Ed); 2018 Jan; 23(2):298-309. PubMed ID: 28930548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subthreshold nitric oxide synthase inhibition improves synergistic effects of subthreshold MMP-2/MLCK-mediated cardiomyocyte protection from hypoxic injury.
    Bil-Lula I; Lin HB; Biały D; Wawrzyńska M; Diebel L; Sawicka J; Woźniak M; Sawicki G
    J Cell Mol Med; 2016 Jun; 20(6):1086-94. PubMed ID: 26992120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Junctophilin-2 is a target of matrix metalloproteinase-2 in myocardial ischemia-reperfusion injury.
    Chan BYH; Roczkowsky A; Cho WJ; Poirier M; Lee TYT; Mahmud Z; Schulz R
    Basic Res Cardiol; 2019 Sep; 114(6):42. PubMed ID: 31506724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nerve influence on myosin light chain phosphorylation in slow and fast skeletal muscles.
    Bozzo C; Spolaore B; Toniolo L; Stevens L; Bastide B; Cieniewski-Bernard C; Fontana A; Mounier Y; Reggiani C
    FEBS J; 2005 Nov; 272(22):5771-85. PubMed ID: 16279942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic analysis of pharmacologically preconditioned cardiomyocytes reveals novel phosphorylation of myosin light chain 1.
    Arrell DK; Neverova I; Fraser H; Marbán E; Van Eyk JE
    Circ Res; 2001 Sep; 89(6):480-7. PubMed ID: 11557734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart.
    Cheung PY; Sawicki G; Wozniak M; Wang W; Radomski MW; Schulz R
    Circulation; 2000 Apr; 101(15):1833-9. PubMed ID: 10769285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury.
    Ali MA; Cho WJ; Hudson B; Kassiri Z; Granzier H; Schulz R
    Circulation; 2010 Nov; 122(20):2039-47. PubMed ID: 21041693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting matrix metalloproteinase-2 reduces protein release into coronary effluent from isolated rat hearts during ischemia-reperfusion.
    Fert-Bober J; Leon H; Sawicka J; Basran RS; Devon RM; Schulz R; Sawicki G
    Basic Res Cardiol; 2008 Sep; 103(5):431-43. PubMed ID: 18512095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myocardial MMP-2 contributes to SERCA2a proteolysis during cardiac ischaemia-reperfusion injury.
    Roczkowsky A; Chan BYH; Lee TYT; Mahmud Z; Hartley B; Julien O; Armanious G; Young HS; Schulz R
    Cardiovasc Res; 2020 Apr; 116(5):1021-1031. PubMed ID: 31373602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the myosin light chain kinase inhibitor ML-7 on the proteome of hearts subjected to ischemia-reperfusion injury.
    Lin HB; Cadete VJ; Sawicka J; Wozniak M; Sawicki G
    J Proteomics; 2012 Sep; 75(17):5386-95. PubMed ID: 22749930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Protective Effect of Simvastatin on the Systolic Function of the Heart in the Model of Acute Ischemia and Reperfusion Is Due to Inhibition of the RhoA Pathway and Independent of Reduction of MMP-2 Activity.
    Skrzypiec-Spring M; Sapa-Wojciechowska A; Rak-Pasikowska A; Kaczorowski M; Bil-Lula I; Hałoń A; Szeląg A
    Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.